Company intelligence / Profile preview

Marsala Biotech Inc.

Winnipeg, Manitoba, Canadabiotech-careers.org ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Marsala Biotech is developing an endostatin-based gene therapy for cancer treatment. There are no published results from late-stage clinical trials or commercialized products as of the latest available data. The company targets unmet needs in oncology with innovative approaches but remains at an early development stage.

Therapeutic areas: Oncology
Modalities: Gene therapy (specifically endostatin gene therapy)Likely biologics (based on gene therapy focus)
Industry: Biotech

Drug pipeline

1 asset

E10A

Phase 3

Indications: Head and neck cancer

Beyond the preview

Go deeper on Marsala Biotech Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marsala Biotech Inc..

Explore the full profile